Previous Close | 14.55 |
Open | 14.55 |
Bid | 14.35 x 500 |
Ask | 14.40 x 500 |
Day's Range | 14.35 - 14.70 |
52 Week Range | 13.23 - 16.45 |
Volume | 72,410 |
Avg. Volume | 307,206 |
Market Cap | 607.116M |
Beta | 0.69 |
PE Ratio (TTM) | 28.14 |
EPS (TTM) | 0.51 |
Earnings Date | Nov 8, 2017 - Nov 13, 2017 |
Forward Dividend & Yield | 0.50 (3.47%) |
Ex-Dividend Date | 2018-02-02 |
1y Target Est | 15.00 |
NEW YORK, April 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
CINCINNATI, April 04, 2018-- Meridian Bioscience, Inc., a leading diagnostic and life science component company, expects to release its second quarter fiscal 2018 operating results before the NASDAQ market ...
New Structure Consists of two Business Units, Diagnostics and Life Science, Supported by a Global Corporate Team Realignment Aimed at Building a Stronger, More Sustainable Organization; Paving the Way ...
SAN DIEGO, CA / ACCESSWIRE / February 12, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain purchasers of NASDAQ: VIVO shares against Meridian Bioscience, Inc. over ...
The healthcare sector has a higher prevalence of companies with sustainable competitive advantages compared to other sectors which implies it may continue generating robust excess returns. When the economy isRead More...
NEW YORK, Feb. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tallgrass ...
LONDON, UK / ACCESSWIRE / February 05, 2018 / Active-Investors.com has just released a free earnings report on Meridian Bioscience, Inc. (NASDAQ: VIVO ) (“Meridian”). If you want access to this report ...
On a per-share basis, the Cincinnati-based company said it had net income of 15 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
CINCINNATI, Jan. 25, 2018-- Meridian Bioscience, Inc. today:. reported first quarter net revenues of $52.3 million, an increase of 12% from the same period of the prior fiscal year; reported first quarter ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Meridian Bioscience, Inc.
NEW YORK, NY / ACCESSWIRE / January 16, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Meridian Bioscience, Inc. ("Meridian Bioscience") ...
NEW YORK, NY / ACCESSWIRE / January 15, 2018 / The Klein Law Firm reminds shareholders that a class action complaint has been filed on behalf of shareholders of Meridian Bioscience, Inc. (NASDAQ: VIVO) ...
NEW ORLEANS , Jan. 12, 2018 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
Glancy Prongay & Murray LLP reminds investors of the January 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Meridian Bioscience, Inc.
NEW YORK, NY / ACCESSWIRE / January 12, 2018 / The Klein Law Firm reminds shareholders that a class action complaint has been filed on behalf of shareholders of Meridian Bioscience, Inc. (NASDAQ: VIVO) ...
NEW YORK, NY / ACCESSWIRE / January 12, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO). ...
The value of the stock shifted after a division of Greater Cincinnati’s 25th-largest public company was cited for alleged violations by a federal agency. The FDA noted that it had issued an advisory to the public in May that Magellan’s LeadCare test systems performed on blood drawn from a vein might provide low results that were erroneous.
NEW YORK, NY / ACCESSWIRE / January 11, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Meridian Bioscience, ...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Meridian Bioscience, Inc. securities between March 25, 2016 and July 13, 2017, inclusive Meridian Bioscience investors have until January 16, 2018 to file a lead plaintiff motion.
NEW YORK, NY / ACCESSWIRE / January 9, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Meridian Bioscience, ...
NEW YORK, NY / ACCESSWIRE / January 9, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Meridian Bioscience, Inc. ("Meridian Bioscience") ...
Glancy Prongay & Murray LLP announces that a class action lawsuit has been filed on behalf of investors that purchased Meridian Bioscience, Inc. securities between March 25, 2016 and July 13, 2017, inclusive .